Latest news with #Ultima
Scoop
24-07-2025
- Business
- Scoop
Ultima NZ Launches Botica Rimu: A Sustainable Timber Solution
Press Release – Ultima NZ Crafted in collaboration with international laminate specialists Greenlam Industries Ltd, Botica Rimu (code BR5375) perfectly replicates the rich grain, warmth, and depth of natural Rimu. Ultima, New Zealand's trusted premium laminate supplier, has launched an innovative new product, Botica Rimu laminate, specifically designed as an authentic yet sustainable alternative to traditional Rimu timber. With genuine Rimu becoming increasingly scarce, especially for large-scale and commercial projects, architects, designers, and specifiers are turning to durable, practical substitutes that respect environmental limits while retaining Rimu's visual charm. Crafted in collaboration with international laminate specialists Greenlam Industries Ltd, Botica Rimu (code BR5375) perfectly replicates the rich grain, warmth, and depth of natural Rimu. Ultima's in-house veneer artisan, Wayne – a timber expert with over 30 years of experience – gave the new laminate his seal of approval, describing it as 'spot on.' Designed explicitly to meet the needs of both residential and commercial projects, Botica Rimu laminate is antibacterial, moisture-resistant, easy to maintain, and extremely durable, making it ideal for kitchens, bathrooms, offices, and retail spaces. Its practical benefits, combined with strikingly realistic texture and colouring, provide a robust solution that can be reliably specified for extensive interior applications. 'Designers are increasingly mindful of sustainability, but they still want the authentic feel of classic materials,' explains Ultima spokesperson. 'Botica Rimu addresses this directly – it's an environmentally responsible, beautifully realistic alternative to a beloved New Zealand native timber.' Botica Rimu laminate is now available nationwide through Ultima, part of the Botica Group. Samples and further information can be requested directly from the website.
Scoop
24-07-2025
- Business
- Scoop
Ultima NZ Launches Botica Rimu: A Sustainable Timber Solution
Ultima, New Zealand's trusted premium laminate supplier, has launched an innovative new product, Botica Rimu laminate, specifically designed as an authentic yet sustainable alternative to traditional Rimu timber. With genuine Rimu becoming increasingly scarce, especially for large-scale and commercial projects, architects, designers, and specifiers are turning to durable, practical substitutes that respect environmental limits while retaining Rimu's visual charm. Crafted in collaboration with international laminate specialists Greenlam Industries Ltd, Botica Rimu (code BR5375) perfectly replicates the rich grain, warmth, and depth of natural Rimu. Ultima's in-house veneer artisan, Wayne - a timber expert with over 30 years of experience - gave the new laminate his seal of approval, describing it as "spot on." Designed explicitly to meet the needs of both residential and commercial projects, Botica Rimu laminate is antibacterial, moisture-resistant, easy to maintain, and extremely durable, making it ideal for kitchens, bathrooms, offices, and retail spaces. Its practical benefits, combined with strikingly realistic texture and colouring, provide a robust solution that can be reliably specified for extensive interior applications. 'Designers are increasingly mindful of sustainability, but they still want the authentic feel of classic materials,' explains Ultima spokesperson. 'Botica Rimu addresses this directly - it's an environmentally responsible, beautifully realistic alternative to a beloved New Zealand native timber.' Botica Rimu laminate is now available nationwide through Ultima, part of the Botica Group. Samples and further information can be requested directly from the website.
Malaysian Reserve
27-06-2025
- Business
- Malaysian Reserve
Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center
FREMONT, Calif., June 26, 2025 /PRNewswire/ — Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform has been selected to support Regeneron Genetics Center® (RGC™) and its recently launched U.S. large-scale proteomics study. The study, comprised of 200,000 blood serum samples secured by RGC from its long-standing research collaboration with Geisinger Health System, will be combined with the recently announced UK Biobank Pharma Proteomics Project, the largest proteomics study undertaken to date, which will also utilize Ultima's UG 100 sequencing platform for the analysis of 600,000 samples from UK consented participants. Combined, these studies reflect the growing role of high-throughput, cost-efficient sequencing in enabling large-scale counting applications across proteomics and other emerging omics fields. For these efforts, RGC will utilize the Olink Explore HT platform and Ultima's UG 100 platform. Ultima's technology was selected for its scalability, efficiency, and suitability for large population-level studies requiring high-throughput data generation. 'We are pleased to continue supporting the ever-expanding large-scale proteomics studies that have the potential to drive important scientific and clinical insights,' said Gilad Almogy, founder and CEO of Ultima Genomics. 'These RGC proteomics studies build on the growing momentum we are seeing for population-scale proteomics and counting applications powered by Ultima's sequencing platform.' About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Ultima Media ContactVikki Herrera408-206-7009vikki@
Associated Press
29-04-2025
- Business
- Associated Press
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
FORT MYERS, Fla. and FREMONT, Calif., April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary ultra-high throughput next-generation sequencing (NGS) platform, today announced a collaboration to use Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance NeoGenomics' ability to offer innovative clinical tests. NeoGenomics has purchased a UG 100 sequencer that will be installed in its innovation center in Cambridge, UK. The UG 100 offers a cost-effective and extremely low-error sequencing profile that is a strong fit for NeoGenomics' emerging clinical assay portfolio that requires large amounts of high-fidelity sequencing data. And with the recent launch of the Solaris portfolio of product advancements, Ultima has now increased sensitivity of variant detection with 5x yield improvements for the SNVQ60 ppmSeq™ mode enabling 30X coverage from as little as 2 nanograms of DNA, making the UG 100 a strong fit for applications like liquid biopsy that require finding a 'needle-in-the haystack.' NeoGenomics' R&D team will use Ultima's UG 100 to enable development of tests spanning the cancer care continuum. 'This collaboration with Ultima, a pioneer in cost-efficient whole genome sequencing, will equip our research and development team with resources to rapidly and efficiently translate innovation for the benefit of patient care,' said Tony Zook, CEO of NeoGenomics. 'With precision oncology testing increasingly being based on next generation sequencing, we are continually looking for targeted opportunities to drive innovation that improve patient outcomes.' 'We are excited to be working with NeoGenomics, a leader in cancer diagnostics with a strong and established footprint in the oncology ecosystem. With the UG 100, NeoGenomics is well-positioned to explore fast-growing markets in oncology diagnostics such as MRD and emerging whole genome sequencing applications,' said Gilad Almogy, CEO of Ultima Genomics. 'Ultima's unique sequencing architecture was designed to specifically meet the needs of cost-effective, large-scale applications and to excel in applications like liquid biopsy requiring extreme accuracy. For oncology applications, our ppmSeq technology offers accuracy at extremely low limits of detection and at low cost, and we believe will be transformational for applications requiring earlier detection such as MRD. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Contacts Ultima Media Contact Vikki Herrera 408-206-7009 [email protected] NeoGenomics Investor Contact Kendra Sweeney [email protected] NeoGenomics Media Contact Andrea Sampson [email protected] View original content to download multimedia: SOURCE Ultima Genomics
